Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,000,000 Ordinary shares of 25 pence each.
- Purchase Date: June 1, 2011.
- Price Range: Highest price paid was 1,323.5 pence per share; lowest price paid was 1,306.5 pence per share.
- Treasury Holdings (Settled): 497,324,284 shares (8.79% of total issued share capital).
- Treasury Holdings (Including Unsettled): 499,174,284 shares (9.67% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,159,568,566 shares.
Material Changes
The primary material change reported is the reduction of outstanding share capital through the cancellation of 1,000,000 repurchased shares. This action increased the proportion of shares held in Treasury to 9.67% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a compliance announcement confirming adherence to shareholder authority and the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,159,568,566) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the impact of the 1,000,000 share cancellation on the total issued share capital.
- Review the price paid (1,306.5 to 1,323.5 pence) against the market price on June 1, 2011.
- Note that the filing does not contain financial performance data; refer to Form 20-F for comprehensive financial statements.